文献速递胸部肿瘤

靶向WEE1克服ARID1A突变驱动的奥希替尼耐药在EGFR突变肺癌中的作用

Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer.
PubMed 文献 · J Thorac Oncol · 2025-06-13

本研究利用软脑膜癌病小鼠模型诱导奥希替尼耐药,发现ARID1A突变是耐药细胞中最常见的突变,ARID1A敲除可导致耐药,而WEE1抑制剂可增强ARID1A突变耐药细胞的凋亡;临床样本分析显示ARID1A突变患者接受奥希替尼治疗的无进展生存期和总生存期显著缩短。结论提示ARID1A突变是奥希替尼耐药的关键生物标志物,WEE1抑制是潜在治疗策略。

要点

  • ARID1A突变是奥希替尼耐药细胞中最常见的突变。
  • ARID1A突变患者接受奥希替尼治疗的中位无进展生存期和总生存期显著缩短。
  • WEE1抑制可增强ARID1A突变奥希替尼耐药细胞的凋亡。

核心结论

  • ARID1A突变是奥希替尼耐药的关键生物标志物,WEE1抑制是ARID1A突变奥希替尼耐药NSCLC的有前景的治疗方法。

研究设计与样本

  • 研究使用软脑膜癌病小鼠模型诱导奥希替尼耐药,并进行下一代测序以表征耐药相关突变。
  • 研究分析了临床样本,以关联ARID1A状态与接受奥希替尼治疗患者的无进展生存期和总生存期。
  • 研究进行了功能实验和CRISPR-Cas9敲除筛选。

主要发现

  • 耐药细胞中ARID1A基因突变最为普遍。
  • 在亲本细胞中敲除ARID1A以及在耐药细胞中表达野生型ARID1A基因是赋予奥希替尼耐药的关键。
  • CRISPR-Cas9敲除筛选鉴定出WEE1激酶是ARID1A突变奥希替尼耐药细胞中凋亡的有效增强剂。
  • ARID1A突变细胞中参与细胞周期调控和DNA修复的基因表达降低,使其对WEE1抑制特别敏感。
  • 在软脑膜癌病小鼠模型中,联合抑制EGFR和WEE1显著抑制了肿瘤生长。

关键数值与推荐

  • ARID1A突变患者接受奥希替尼治疗的中位无进展生存期为6.25个月,野生型ARID1A患者为18.0个月(p=0.0036)。
  • ARID1A突变患者接受奥希替尼治疗的中位总生存期为17.0个月,野生型ARID1A患者为34.0个月(p=0.024)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Osimertinib, a third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is commonly used as a first-line treatment for EGFR-mutant NSCLC. Nevertheless, despite its efficacy, resistance remains a major clinical challenge with unknown underlying mechanisms. This study aimed to investigate the mechanisms driving osimertinib resistance and identify therapeutic strategies. METHODS: Using a mouse model of leptomeningeal carcinomatosis, we induced osimertinib resistance and performed next-generation sequencing to characterize resistance-associated mutations. We also analyzed clinical samples to correlate ARID1A status with progression-free survival and overall survival in patients receiving osimertinib. RESULTS: Mutations in the AT-rich interacting domain-containing protein 1A (ARID1A) gene were the most prevalent in resistant cells. Functional assays revealed that ARID1A knockout in parental cells and wild-type ARID1A gene expression in resistant cells were critical in conferring osimertinib resistance. A Clustered Regularly Interspaced Short Palindromic Repeats-Cas9 knockout screen identified WEE1 kinase as a potent enhancer of apoptosis in ARID1A-mutant osimertinib-resistant cells. Mechanistically, ARID1A-mutant cells exhibited reduced expression of genes involved in cell cycle regulation and DNA repair, rendering them particularly sensitive to WEE1 inhibition. In the leptomeningeal carcinomatosis mouse model, the combined inhibition of EGFR and WEE1 significantly suppressed tumor growth. Clinically, patients with ARID1A mutations treated with osimertinib had significantly shorter median progression-free survival (6.25 versus 18.0 months, p = 0.0036) and overall survival (17.0 versus 34.0 months, p = 0.024) than did those with wild-type ARID1A. CONCLUSIONS: These findings suggest that ARID1A mutations are critical biomarkers for osimertinib resistance and highlight WEE1 inhibition as a promising therapeutic approach for ARID1A-mutant osimertinib-resistant NSCLC.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Fukuda K, Nanjo S, Takeuchi S, et al. Targeting WEE1 to Overcome ARID1A Mutation-Driven Osimertinib Resistance in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2025. PMID: 40518016. doi:10.1016/j.jtho.2025.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。